Funding for this research was provided by:
National Cancer Institute (R01CA167821, P30CA012197, R01CA199167)
National Heart, Lung, and Blood Institute (R01HL118740)
Received: 27 December 2018
Accepted: 17 April 2019
First Online: 3 May 2019
Ethics approval and consent to participate
: This research involved human subjects and was performed in accordance with the Declaration of Helsinki. All participants provided informed consent. This study was approved by the Institutional Review Board of the Wake Forest University School of Medicine.
: Study participants agreed to have their data used in publications.
: The authors have the following disclosures to declare: Dr. Kitzman has been a consultant for Relypsa, Abbvie, GlaxoSmithKline, AstraZeneca, Merck, CinRx, St. Luke’s Medical Center, DCRI, and Corvia Medical; received grants from Novartis and St. Luke’s Medical Center; and owns stock in Gilead Sciences.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.